A breast cancer patient recently wrote to us at CANCERactive. She is 52 and has breast cancer, ER+ and Her-2+.
The programme being offered offered by her oncologist is:
Surgery plus radiotherapy, then
3 rounds FEC
3 rounds FEC-T
Tamoxifen then an Aromatase Inhibitor
Herceptin
Her oncologist provided the following data:
5-year survival
40 out of 100 women are alive at 5 years with no adjuvant therapy after surgery
An extra 13 out of 100 women treated are alive because of hormone therapy
An extra 30 out of 100 women treated are alive because of hormone therapy & chemotherapy
An extra 37 out of 100 women treated are alive because of hormone therapy, chemotherapy and Trastuzumab
Total 77 out of 100
10-year survival
12 out of 100 women are alive at 10 years with no adjuvant therapy after surgery
An extra 11 out of 100 women treated are alive because of hormone therapy
An extra 32 out of 100 women treated are alive because of hormone therapy & chemotherapy
An extra 37 out of 100 women treated are alive because of hormone therapy, chemotherapy and Trastuzumab
Total 49 out of 100
According to the Eurocare studies, breast cancer treatment is the best performing area of orthodox treatment.